Effect and mechanism of peroxisome proliferator-activated receptor-γ on the drug resistance of the U-87 MG/CDDP human malignant glioma cell line

Han,Shaorong; Lv,Xiaoyan; Wang,Yanming; Gong,Hai; Zhang,Cong; Tong,Anna; Zhang,Baoyi; Yao,Hui

doi:10.3892/mmr.2015.3625

Effect and mechanism of peroxisome proliferator-activated receptor-γ on the drug resistance of the U-87 MG/CDDP human malignant glioma cell line

Authors:
- Shaorong Han
- Xiaoyan Lv
- Yanming Wang
- Hai Gong
- Cong Zhang
- Anna Tong
- Baoyi Zhang
- Hui Yao
View Affiliations

Affiliations: Department of Radiation Oncology, Jinan Military General Hospital, Jinan, Shandong 250031, P.R. China
Published online on: April 16, 2015 https://doi.org/10.3892/mmr.2015.3625
Pages: 2239-2246

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Peroxisome proliferator-activated receptor-γ (PPAR-γ) is important in tumor differentiation, proliferation and apoptosis. However, the effect and mechanism of PPAR‑γ on the promotion of cisplatin sensitivity in glioma cells remain to be elucidated. The present study established cisplatin‑resistant U‑87 MG/CDDP cell lines and U‑87 MG/CDDP cell lines overexpressing PPAR‑γ. With upregulated expression of PPAR‑γ, the sensitivity of cancer cells to cisplatin was increased. Flow cytometry revealed that the intracellular content of rhodamine‑123 was increased, expression of P‑glycoprotein was downregulated, cell cycle was arrested in G0/G1 phase, apoptosis and oxidative stress was increased, levels of intracellular thymidylate synthase, glutathione and transforming growth factor‑β1 were decreased, expression levels of multidrug resistance related gene (MDR), multidrug resistance‑associated protein and glutothionine S‑transferase‑π were downregulated, expression levels of cell proliferation and apoptosis associated genes, including survivin and B‑cell lymphoma‑2, were downregulated, p53, p21 and caspase‑3/8 were significantly upregulated, phosphorylation of extracellular signal‑regulated kinase and small mothers against decapentaplegic 2 were downregulated, and the transcriptional activities of Twist and nuclear factor (erythroid‑derived 2)‑like 2 were significantly reduced. The results suggested that upregulation of PPAR‑γ in the U‑87 MG/DDP cells increased cisplatin sensitivity, and the underlying mechanisms included the regulation of MDR and apoptosis associated genes, which increased the intracellular accumulation of the drug, inhibited cell proliferation and promoted cell apoptosis.

View Figures

View References

1	Shete S, Lau CC, Houlston RS, et al: Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the Gliogene consortium. Cancer Res. 71:7568–7575. 2011. View Article : Google Scholar : PubMed/NCBI
2	Sabo B: Primary malignant brain tumours, psychosocial distress and the intimate partner experience: what do we know? Can J Neurosci Nurs. 3:9–15. 2014.
3	Zhou LF: The first step in a long-run-celebrating the announcement of ‘Guideline for the management of CNS gliomas in China’. Zhonghua Yi Xue Za Zhi. 93:24172013.In Chinese.
4	Yang P, Wang Y, Peng X, et al: Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neurooncol. 113:259–266. 2013. View Article : Google Scholar : PubMed/NCBI
5	Wu JS, Zhang J, Zhuang DX, et al: Current status of cerebral glioma surgery in China. Chin Med J (Engl). 124:2569–2577. 2011.
6	Wang J, Liu X, Ba YM, et al: Effect of sonographically guided cerebral glioma surgery on survival time. J Ultrasound Med. 31:757–762. 2012.PubMed/NCBI
7	Diaz-Miqueli A and Martinez GS: Nimotuzumab as a radiosen-sitizing agent in the treatment of high grade glioma: challenges and opportunities. Onco Targets Ther. 6:931–942. 2013. View Article : Google Scholar
8	Wu Z, Chan CL, Eastman A and Bresnick E: Expression of human O6-methylguanine-DNA methyltransferase in Chinese hamster ovary cells and restoration of cellular resistance to certain N-nitroso compounds. Mol Carcinog. 4:482–488. 1991. View Article : Google Scholar : PubMed/NCBI
9	Wang Y, Liu L, Liu X, et al: Shugoshin1 enhances multidrug resistance of gastric cancer cells by regulating MRP1, Bcl-2 and Bax genes. Tumour Biol. 34:2205–2214. 2013. View Article : Google Scholar : PubMed/NCBI
10	Cheung KK, Chan JY and Fung KP: Antiproliferative effect of pheophorbide a-mediated photodynamic therapy and its synergistic effect with doxorubicin on multiple drug-resistant uterine sarcoma cell MES-SA/Dx5. Drug Chem Toxicol. 36:474–483. 2013. View Article : Google Scholar : PubMed/NCBI
11	Ching J, Amiridis S, Stylli SS, et al: A novel treatment strategy for glioblastoma multiforme and glioma associated seizures: increasing glutamate uptake with PPARγ agonists. J Clin Neurosci. 1:21–28. 2015. View Article : Google Scholar
12	Abbott BD: Review of the expression of peroxisome prolif-erator-activated receptors alpha (PPAR alpha), beta (PPAR beta) and gamma (PPAR gamma) in rodent and human development. Reprod Toxicol. 27:246–257. 2009. View Article : Google Scholar
13	Khoo NK, Hebbar S, Zhao W, et al: Differential activation of catalase expression and activity by PPAR agonists: implications for astrocyte protection in anti-glioma therapy. Redox Biol. 1:70–79. 2013. View Article : Google Scholar : PubMed/NCBI
14	Bai Y, Liao H, Liu T, et al: MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-à-go-go (EAG1). Eur J Cancer. 49:710–724. 2013. View Article : Google Scholar
15	Reka AK, Goswami MT, Krishnapuram R, et al: Molecular cross-regulation between PPAR-γ and other signaling pathways: implications for lung cancer therapy. Lung Cancer. 72:154–159. 2011. View Article : Google Scholar : PubMed/NCBI
16	Kawai M and Rosen CJ: PPARγ: a circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol. 6:629–636. 2010. View Article : Google Scholar : PubMed/NCBI
17	Siersbaek R, Nielsen R and Mandrup S: PPARgamma in adipocyte differentiation and metabolism-novel insights from genome-wide studies. FEBS Lett. 584:3242–3249. 2010. View Article : Google Scholar : PubMed/NCBI
18	Martín V, Sanchez-Sanchez AM, Herrera F, et al: Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer. 108:2005–2012. 2013. View Article : Google Scholar : PubMed/NCBI
19	Quezada C, Peigñan L, Segura R, et al: Study of resistance to chemotherapy mediated by ABC transporters in biopsies of glioblastoma multiforme. Rev Med Chil. 139:415–424. 2011.In Spanish. View Article : Google Scholar : PubMed/NCBI
20	Garrido W, Muñoz M, San Martín R and Quezada C: FK506 confers chemosensitivity to anticancer drugs in glioblastoma multiforme cells by decreasing the expression of the multiple resistance-associated protein-1. Biochem Biophys Res Commun. 411:62–68. 2011. View Article : Google Scholar : PubMed/NCBI
21	Shityakov S and Förster C: Multidrug resistance protein P-gp interaction with nanoparticles (fullerenes and carbon nanotube) to assess their drug delivery potential: a theoretical molecular docking study. Int J Comput Biol Drug Des. 6:343–357. 2013. View Article : Google Scholar : PubMed/NCBI
22	Zhu FS, Chen XM, Huang ZG, et al: Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells. J Dig Dis. 11:34–42. 2010. View Article : Google Scholar : PubMed/NCBI
23	Zhou YT, Li K and Tian H: Effects of vinorelbine on cisplatin resistance reversal in human lung cancer A549/DDP cells. Asian Pac J Cancer Prev. 14:4635–4639. 2013. View Article : Google Scholar : PubMed/NCBI
24	Ryan BM, O’Donovan N and Duffy MJ: Survivin: a new target for anti-cancer therapy. Cancer Treat Rev. 35:553–562. 2009. View Article : Google Scholar : PubMed/NCBI
25	Horowitz JC, Ajayi IO, Kulasekaran P, et al: Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis. Int J Biochem Cell Biol. 44:158–169. 2012. View Article : Google Scholar
26	Zhu Y, Liu XJ, Yang P, et al: Alkylglyceronephosphate synthase (AGPS) alters the lipids signaling pathways and support the chemotherapy resistance of glioma and hepatic carcinoma cell lines. Asian Pac J Cancer Prev. 15:3219–3226. 2014. View Article : Google Scholar
27	Bharatham N, Chi SW and Yoon HS: Molecular basis of Bcl-X(L)-p53 interaction: insights from molecular dynamics simulations. PLoS One. 6:e260142011. View Article : Google Scholar : PubMed/NCBI
28	Zandbergen F, Mandard S, Escher P, et al: The G0/G1 switch gene 2 is a novel PPAR target gene. 392:313–324. 2005.
29	Yuan L, Zhang Y, Xia J, et al: Resveratrol induces cell cycle arrest via a p53-independent pathway in A549 cells. Mol Med Rep. 4:2459–2464. 2015.
30	Liu LC, Tsao TC, Hsu SR, et al: EGCG inhibits transforming growth factor-β-mediated epithelial-to-mesenchymal transition via the inhibition of Smad2 and Erk1/2 signaling pathways in nonsmall cell lung cancer cells. J Agric Food Chem. 60:9863–9873. 2012. View Article : Google Scholar : PubMed/NCBI
31	Gilmore TD: Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 25:6680–6684. 2006. View Article : Google Scholar : PubMed/NCBI
32	Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 9:537–549. 2009. View Article : Google Scholar : PubMed/NCBI
33	Nakamura T, Toita H, Yoshimoto A, et al: Potential involvement of Twist2 and Erk in the regulation of osteoblastogenesis by HB-EGF-EGFR signaling. Cell Struct Funct. 35:53–61. 2010. View Article : Google Scholar : PubMed/NCBI